Compare PCB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | OCGN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 387.3M |
| IPO Year | N/A | N/A |
| Metric | PCB | OCGN |
|---|---|---|
| Price | $21.62 | $1.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $7.00 |
| AVG Volume (30 Days) | 27.4K | ★ 3.9M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $107,743,000.00 | $5,370,000.00 |
| Revenue This Year | $21.55 | $35.93 |
| Revenue Next Year | $8.65 | N/A |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | 13.61 | ★ 14.26 |
| 52 Week Low | $16.00 | $0.52 |
| 52 Week High | $24.04 | $1.90 |
| Indicator | PCB | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 48.84 |
| Support Level | $23.03 | $1.34 |
| Resistance Level | $24.04 | $1.53 |
| Average True Range (ATR) | 0.59 | 0.11 |
| MACD | -0.23 | 0.00 |
| Stochastic Oscillator | 2.76 | 36.49 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").